Your browser is no longer supported. Please, upgrade your browser. Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
AVNR [NASD]
Avanir Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.47 Insider Own0.60% Shs Outstand192.76M Perf Week5.48%
Market Cap2.67B Forward P/E- EPS next Y-0.43 Insider Trans-4.70% Shs Float189.90M Perf Month18.87%
Income-71.80M PEG- EPS next Q-0.06 Inst Own65.80% Short Float7.84% Perf Quarter138.97%
Sales104.00M P/S25.69 EPS this Y-17.80% Inst Trans-0.06% Short Ratio2.45 Perf Half Y186.36%
Book/sh0.40 P/B34.65 EPS next Y-48.30% ROA-84.50% Target Price17.71 Perf Year224.59%
Cash/sh0.44 P/C31.43 EPS next 5Y19.20% ROE-235.50% 52W Range2.62 - 14.20 Perf YTD312.50%
Dividend- P/FCF- EPS past 5Y-14.40% ROI-149.40% 52W High-2.39% Beta0.92
Dividend %- Quick Ratio3.00 Sales past 5Y60.90% Gross Margin94.60% 52W Low429.01% ATR0.62
Employees267 Current Ratio3.10 Sales Q/Q44.40% Oper. Margin-65.60% RSI (14)68.41 Volatility3.76% 5.02%
OptionableYes Debt/Eq0.36 EPS Q/Q0.00% Profit Margin-68.90% Rel Volume0.27 Prev Close13.57
ShortableYes LT Debt/Eq0.19 EarningsDec 08 Payout- Avg Volume6.07M Price13.86
Recom1.70 SMA207.43% SMA5015.99% SMA200110.27% Volume1,634,878 Change2.14%
May-02-14Upgrade Mizuho Neutral → Buy $5 → $10
Dec-11-13Downgrade Mizuho Buy → Neutral $11 → $5
Jul-12-13Reiterated Mizuho Buy $10 → $11
Jul-08-13Reiterated Summer Street Research Buy $14 → $16
Jun-14-13Initiated Mizuho Buy $10
Aug-23-11Initiated JMP Securities Mkt Outperform $7
Nov-02-10Reiterated Wedbush Outperform $9 → $13
Oct-07-10Reiterated Canaccord Genuity Buy $6 → $9
Jul-01-10Initiated Jefferies Buy $10
Apr-29-10Initiated Wedbush Outperform $9
Apr-06-10Initiated Canaccord Adams Buy $6
Apr-06-10Initiated Canaccord Adams Buy
Jan-29-10Initiated Merriman Buy
Mar-01-07Reiterated Punk, Ziegel & Co Sell $2 → $1.25
Feb-27-07Upgrade Wedbush Morgan Sell → Hold $1.50
Nov-20-14 09:00AM  Avanir Pharmaceuticals to Participate in Two Conferences in December PR Newswire
Nov-12-14 04:48PM  AVANIR PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
08:00AM  Avanir's AVP-825 Approval Could be Delayed (Revised) Zacks
Nov-10-14 04:40PM  Avanir Faces Regulatory Setback, AVP-825 Could Be Delayed Zacks
Nov-07-14 04:28PM  Another lackluster session for major equities Yahoo Finance Blogs
03:04PM  AVANIR PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
12:35PM  Midday movers: Allergan, Freshpet, Transocean & more at CNBC
11:25AM  Avanir Pharmaceuticals (AVNR) Stock Drops After FDA Provides New Drug Application Feedback at TheStreet
08:30AM  Avanir Pharmaceuticals Announces Preliminary Feedback from the FDA on AVP-825 for the Acute Treatment of Migraine PR Newswire
Nov-04-14 08:52AM  Will Avanir Pharmaceuticals (AVNR) Stock React Today to This Analyst Action? at TheStreet
Oct-31-14 10:19AM  Perilous Reversal Stock: AVANIR Pharmaceuticals (AVNR) at TheStreet
Oct-30-14 04:01PM  Avanir Pharmaceuticals Announces Publication of Pivotal Phase III Results from AVP-825 Acute Migraine Study in the Journal "Headache" PR Newswire +6.54%
Oct-22-14 03:10PM  6 stocks to watch at MarketWatch
Oct-17-14 07:05AM  Biotech Stock Mailbag: Small-Cap Rebound, Avanir, Ohr, CytoSorbents at TheStreet
Oct-15-14 05:04PM  Concert Pharmaceuticals Announces Positive CTP-354 Data Zacks
Oct-14-14 05:05PM  Avanir (AVNR) Presents Detailed Phase II Data on AVP-923 Zacks
Oct-13-14 04:26PM  Avanir Pharmaceuticals Announces Presentation of AVP-923 Phase II Results in Agitation in Patients with Alzheimer's Disease at the American Neurological Association Meeting PR Newswire
Oct-08-14 04:15PM  Avanir Pharmaceuticals to Host Investor Briefing on October 15, 2014 PR Newswire
08:30AM  Avanir Pharmaceuticals Announces Data Presentations at the American Neurological Association's (ANA) 2014 Annual Meeting Including Results from the Phase II Trial for Treatment of Agitation in Patients with Alzheimer's Disease PR Newswire
Oct-01-14 06:49PM  Lightning Round: Manitowoc, Harman Int'l & more at CNBC
Sep-29-14 09:15AM  Avanir Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares PR Newswire
Sep-25-14 03:09PM  AVANIR PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and EDGAR Online
Sep-24-14 11:06AM  Avanir Pharma prices $200M stock offering AP
10:10AM  How Will Public Offering Pricing Affect Avanir Pharmaceuticals (AVNR) Stock Today? at TheStreet
Sep-23-14 10:00PM  Avanir Pharmaceuticals Announces Pricing of Public Offering of Common Stock PR Newswire
03:13PM  Dow Down 0.6%; CarMax Shares Fall After Q2 Results Benzinga
11:20AM  Markets Mixed; Carnival Profit Tops Street View Benzinga
Sep-22-14 04:45PM  Avanir Pharmaceuticals Announces Proposed Public Offering of Common Stock PR Newswire
Sep-19-14 06:02PM  Nasdaq stocks posting largest percentage decreases AP -5.48%
06:59AM  Weakness Seen in Avanir Pharmaceuticals (AVNR): Stock Falls 6.5% Zacks
Sep-18-14 03:46PM  4 stocks to watch at MarketWatch -6.49%
10:30AM  Insider Trading Alert - RSG, HAL And AVNR Traded By Insiders at TheStreet
08:25AM  The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead Zacks
Sep-16-14 04:44PM  Glimcher and Apple are big market movers AP
03:40PM  Avanir Pharmaceuticals Shoots Up on Positive AVP-923 Data Zacks
10:00AM  Is Avanir Pharma Fully Valued After Mondays Rally? at 24/7 Wall St.
09:16AM  How to Trade the Market's Most-Active Stocks: RATE, AVNR, NPSP, TAP at TheStreet
07:33AM  The Zacks Analyst Blog Highlights: Merck KGaA, Lannett, Avanir Pharmaceuticals, Anacor Pharmaceuticals and Helen of Troy Zacks
Sep-15-14 06:53PM  Avanir Pharmaceuticals Investor's Business Daily +85.31%
05:15PM  Technology Stocks Down As Rest Of The Market Starts Week Flat Benzinga
04:49PM  [video] U.S. Stocks Close Mixed with Nasdaq Slammed by Sell-off at TheStreet
04:32PM  US STOCKS-Nasdaq slumps to worst day since July; S&P 500 dips Reuters
04:19PM  Taking Stock: Winners and Losers, Stock of the Day at Bloomberg
03:40PM  Terex Falls After Lowered Earnings Forecast; Avanir Pharmaceuticals Shares Surge Benzinga
03:15PM  US STOCKS-Tech shares drag Nasdaq, S&P 500 little changed Reuters
02:50PM  Avanir Pharma soars on agitation drug study AP
01:40PM  Midday movers: Apple, Netflix, RadioShack & more at CNBC
01:25PM  Nasdaq stocks posting largest percentage increases AP
01:24PM  NASDAQ Tumbles 1.1%; Alere Shares Surge Following Proposed $46/Share Offer Benzinga
01:20PM  Why Avanir Pharmaceuticals (AVNR) Stock Soared to a One-Year High Today at TheStreet
12:43PM  AVANIR PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
12:42PM  US STOCKS-Nasdaq loses ground as tech sector weighs Reuters
12:32PM  Midday Gainers From September 15 - RadioShack Corporation, Rewalk Robotics Ltd And More Benzinga
11:26AM  Markets Fall; Cognizant To Acquire TriZetto For $2.7 Billion Benzinga
11:26AM  US STOCKS-Wall St little changed but tech weighs on Nasdaq Reuters
10:35AM  Alzheimers Study Results Take Avanir Back Up to Multiyear Highs at 24/7 Wall St.
10:19AM  Avanir's Over-Priced Cough Syrup Touted For Role in Alzheimer's Agitation at TheStreet
08:30AM  Avanir Pharmaceuticals Announces Positive Phase II Trial Results for AVP-923 in Treatment of Agitation in Patients with Alzheimer's Disease PR Newswire
Sep-11-14 07:19AM  Avanir Pharmaceuticals (AVNR) in Focus: Stock Surges 14.4% Zacks
Sep-10-14 12:48PM  U.S. Stocks Rise; Palo Alto Networks Shares Surge On Upbeat Revenue Benzinga +14.50%
Sep-03-14 01:00PM  Tetraphase (TTPH) Up on IGNITE 2 Results on Eravacycline Zacks
Sep-02-14 09:00AM  Avanir Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference PR Newswire
Aug-27-14 02:00PM  Avanir Doses First Patient with AVP-786, Updates on AVP-923 Zacks
Aug-26-14 09:00AM  Avanir Pharmaceuticals Announces Initiation of Phase II Study of AVP-786 for the Adjunctive Treatment of Major Depressive Disorder PR Newswire
08:54AM  Will Avanir (AVNR) Continue to Surge Higher? Zacks
Aug-21-14 03:47PM  5 companies that will benefit from ALS awareness at MarketWatch
Aug-15-14 01:04PM  AVANIR PHARMACEUTICALS, INC. Financials EDGAR Online Financials
Aug-14-14 09:58AM  Biodel Q3 Loss Narrower than Expected, Gives Pipeline Update Zacks
Aug-07-14 06:03AM  AVANIR PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report EDGAR Online
Aug-06-14 03:10PM  Avanir's Q3 Loss in Line, Revenues Up on High Nuedexta Demand Zacks
Aug-05-14 04:30PM  Avanir Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today CCBN
04:21PM  AVANIR PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements EDGAR Online
04:01PM  Avanir Pharmaceuticals Reports Fiscal 2014 Third Quarter Financial and Business Update PR Newswire
08:30AM  Avanir Pharmaceuticals to Participate in Two Conferences in August PR Newswire
07:07AM  Q3 2014 Avanir Pharmaceuticals Earnings Release - After Market Close CCBN
Jul-28-14 08:30AM  Avanir Pharmaceuticals Announces Date of Fiscal 2014 Third Quarter Financial Results and Conference Call GlobeNewswire
Jul-21-14 09:15AM  Avanir Pharmaceuticals Announces FDA Acceptance of IND for AVP-786 for the Adjunctive Treatment of Major Depressive Disorder PR Newswire
Jul-16-14 09:00AM  Avanir Pharmaceuticals Announces Presentation of Positive Early Results from PRISM II Study PR Newswire
Jul-11-14 07:00AM  3 Biotech Stocks Under $10 to Trade for Breakouts at TheStreet
Jul-09-14 10:40AM  Concert Pharmaceuticals' Shares Slip Despite Favorable FDA Meeting Zacks
Jun-30-14 07:22PM  Avanir Pharmaceuticals Announces Two Data Presentations Related to Pseudobulbar Affect (PBA) at the Alzheimer's Association International Conference (AAIC) PR Newswire
Jun-25-14 08:34AM  3 Health Care Stocks Under $10 to Trade for Breakouts
Jun-24-14 08:38AM  Avanir to present data related to safety and efficacy of AVP-825 at theflyonthewall.com
08:30AM  Avanir Pharmaceuticals Announces Three Data Presentations Related to AVP-825 for the Acute Treatment of Migraine at the American Headache Society Annual Meeting PR Newswire
Jun-12-14 11:10AM  Avanir Gains - AVP-825 Hits Phase III Primary Endpoint Zacks
Jun-10-14 04:00AM  Avanir Pharmaceuticals Announces Positive Outcome of Phase IIIb COMPASS Trial: A Head-to-Head Study Comparing AVP-825 to Oral Sumatriptan for the Acute Treatment of Migraine PR Newswire
Jun-03-14 06:34AM  Ignyta (RXDX) Jumps: Stock Adds 12.7% in Session Zacks
Jun-02-14 05:25PM  Patients Enrolled in Avanir Study Zacks
04:00PM  Pipeline Update from Avanir Zacks
07:46AM  NPS Pharmaceuticals (NPSP) in Focus: Stock Rises 13.4% Zacks
May-30-14 09:00AM  Avanir Pharmaceuticals Announces Multiple Data Presentations Related to Pseudobulbar Affect (PBA) Prevalence and Treatment at Two Conferences in June PR Newswire
May-28-14 09:00AM  Avanir Pharmaceuticals to Participate in Two Conferences in June PR Newswire
May-27-14 09:01AM  Avanir completes patient enrollment in study of AVP-923 at theflyonthewall.com
09:00AM  Avanir Pharmaceuticals Announces Completion of Patient Enrollment in Study of AVP-923 for the Treatment of Agitation in Patients with Alzheimer's Disease PR Newswire
May-15-14 10:06AM  Stock To Watch: AVANIR Pharmaceuticals (AVNR) In Perilous Reversal at TheStreet
07:53AM  Avanir (AVNR) Shares March Higher, Can It Continue? Zacks
03:42AM  Avanir Pharmaceuticals (AVNR) in Focus: Stock Moves 6.1% Higher Zacks
May-14-14 07:21AM  QLT Inc. (QLTI) Falls: Stock Goes Down 9.13% Zacks +6.09%
May-09-14 09:20AM  Avanir financial overhang removed, says JMP Securities at theflyonthewall.com +6.10%
May-08-14 04:00PM  Avanir Loss In Line with Ests, Revs Up Zacks
Avanir Pharmaceuticals, Inc., together with its subsidiaries, is engaged in acquiring, developing, and commercializing novel therapeutic products for the treatment of central nervous system disorders primarily in the United States. It primarily offers NUEDEXTA, a dual N-methyl-D-aspartate receptor antagonist and sigma-1 agonist for the treatment of pseudobulbar affect; and Docosanol 10% cream, an over-the-counter product for the treatment of cold sores. The company's clinical development stage products comprise AVP-923, which has completed Phase II clinical trials for the treatment of central neuropathic pain in patients with multiple sclerosis; is in Phase II clinical trials for the treatment of agitation in patients with Alzheimer's disease; and is in Phase II clinical trials for the treatment of levodopa-induced-dyskinesia in Parkinson's disease, as well as completed Phase III trials for the treatment of patients with diabetic peripheral neuropathic pain. It is also developing AVP-786, a Phase I clinical trial novel investigational drug product for the treatment of neurologic and psychiatric disorders; and AVP-825, an investigational drug-device combination product, which is in Phase III clinical trials, to treat acute migraine. The company has a license agreement with Concert Pharmaceuticals, Inc. to develop and commercialize deuterium-modified dextromethorphan for the potential treatment of neurologic and psychiatric disorders, as well as rights to other deuterium-modified dextromethorphan compounds; and a license agreement with OptiNose AS for the development and commercialization of a novel breath powered intranasal delivery system to treat acute migraine. Avanir Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Aliso Viejo, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
OCAMPO CHRISTINEVice President, FinanceOct 24Sale11.812,08024,56577,791Oct 24 08:22 PM
Siffert Joao MDSVP, R&DOct 24Sale11.808,42699,427222,554Oct 24 08:48 PM
OCAMPO CHRISTINEVice President, FinanceSep 15Sale9.4555,000519,75079,871Sep 17 08:44 PM
PALEKAR ROHANSVP & Chief Commercial OfficerSep 15Sale11.5025,000287,500266,750Sep 17 08:28 PM
OCAMPO CHRISTINEVice President, FinanceAug 26Sale6.102,11012,87179,871Aug 28 09:03 PM
Katkin KeithPresident and CEOAug 01Sale5.269,67050,864760,412Aug 01 08:44 PM
Katkin KeithPresident and CEOMay 28Sale5.01442,2122,215,482750,082May 30 08:00 PM
OCAMPO CHRISTINEVice President, FinanceMay 16Sale4.8811,90058,0723,000May 16 08:00 PM
OCAMPO CHRISTINEVice President, FinanceMay 14Sale5.1325,596131,30781,981May 16 08:00 PM
Siffert Joao MDSVP, R&DDec 18Sale2.635,97015,713110,230Dec 20 05:32 PM
OCAMPO CHRISTINEVice President, FinanceDec 18Sale2.632,4506,44563,202Dec 20 05:26 PM
Katkin KeithPresident and CEODec 18Sale2.6729,51578,935445,707Dec 20 05:24 PM
PALEKAR ROHANSVP & Chief Commercial OfficerDec 17Buy2.8010,00028,000143,000Dec 19 04:31 PM